CHNC Aims to Be the Global Leader in Cannabis Clinical Trials Through a Merger with Pharmacology University

Houston, TX - (NewMediaWire) - October 28, 2020 - CHNC (OTC Pink: CHNC) announces its merger with Pharmacology University, Inc., a global leader in the field of medical cannabis education that markets its services under the brand Pharmacology University. More to the point, CHNC joining forces with Pharmacology University Inc. and Precision Research Institute has created one of the most complete companies in the cannabis industry. COO Elizabeth Hernandez explains the reasons behind the decision: "While pursuing my dream, I had wanted to unite forces with a company in the Cannabis Industry and that is when I found Pharmacology University. The synergy between the two companies has been superb and we are positioning ourselves to become the high-end authority of the Cannabis Research Industry. Now this journey finally feels complete. Riding this new wave of inspiration, we are deeply committed to produce revenue generating models and building shareholder value."

Cannot view this video? Visit:

The merger of CHNC, which is publicly traded on OTC markets under the ticker symbol CHNC, provides the framework for Pharmacology University to expand its focus into cannabis clinical trials and bolstering its education offerings.

Founded in 2010, Pharmacology University offers educational products and consulting services in the United States, Puerto Rico, Latin and South America; to train doctors, dispensary owners, growers, lawyers, and other professionals on the palliative and myriad health benefits of cannabis. The company also has partnered with private accredited universities to offer an intensive master's certification program in cannabis science and is now the top international provider of medical cannabis education.

In addition to its classroom education, Pharmacology University owns and operates Canna Law Magazine, which is a digital informational piece that provides cultural enrichment to the cannabis entrepreneur. The magazine has biweekly editions and informs the public about the most recent legal cases in the cannabis industry worldwide, also providing strategies by which its readers can avoid finding themselves in legal situations for lack of knowledge. Canna Law Magazine is currently available in English, Spanish, Portuguese, Italian and Arabic, and it is being developed to be published in Chinese and Hindi. To view the magazine, visit

"We want to be pioneers in the search for the truth with actual clinical trials, in regards to how cannabis can be utilized," says Pharmacology University In-House Legal Counsel, Anne Graham. "Predominantly because the number one problem for people that are set against using cannabis as medicine is simply due to the fact that the cannabis industry has not produced sufficient medical studies," she says.

The global market for medical cannabis (also known as medical marijuana), is expected to reach more than $150 billion annually by 2027, according to a 2019 report by The anticipated growth is driven in large part by the legalization of cannabis for medical use in Europe, as well as the passage in the U.S. of the Hemp Farming Act of 2018, which legalized hemp, a variety of the Cannabis Sativa species that has less than 0.3% concentration of tetrahydrocannabinol (THC). And although many companies are looking to capitalize on the industry's projected growth by opening dispensaries, cannabis farms, or manufacturing facilities, Pharmacology University sees limitless opportunities in the education space.

Says Dr. Jose Torres, International Medical Director for Pharmacology University, "The endocannabinoid system is represented in every organ and system in the body. That means that at times, we could have deficiencies, just like now and again, our bodies present insufficiencies of minerals and vitamins; accordingly, the human body could also lack endocannabinoids." Preliminary research indicates that the scarcity of endocannabinoids may be the root of various illnesses, such as epilepsy and even certain types of cancer, he adds. By becoming a pioneer in clinical trials to explore more than 120 cannabis molecules, the newly formed public company aims to equip healthcare professionals and others in the industry with the information and knowledge to help millions of people through the use of cannabis in medical treatments.

"We had a vision when we started ten years ago, and 2021 will be our dream becoming a reality," says Katerin Osuna, International Director of Marketing and Public Relations of Pharmacology University, Magister in Audiovisual Communications and Advertising Content, from the Autónoma University of Barcelona, Spain. "We look forward to being the world leader in cannabis clinical studies."

About Pharmacology University

Pharmacology University, which markets its educational products under the brand Pharmacology University, aims to eliminate outmoded taboos and political obstacles surrounding medical cannabis to help alleviate the physical pain and suffering; whereby improving the quality of life for millions of people worldwide. The company is determined to vastly increase the number of patients who will benefit from cannabis medication through clinical trials, education, and lobbying efforts that appeal to the compassion of legislators in the United States and around the world. For more information please visit and view us here

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

Media Contact: 

Henry Levinski
(817) 528-2475

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.